Gamida Cell Announces Launch of Public Offering of Securities
April 18 2023 - 7:16PM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working
to turn cells into powerful therapeutics, today announced the
launch of a follow-on public offering of its ordinary shares and
accompanying warrants to purchase its ordinary shares. In addition,
Gamida Cell expects to grant the underwriters a 30-day option to
purchase up to an additional 15% of the ordinary shares to be sold
in the offering and/or warrants to purchase its ordinary shares on
the same terms and conditions. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed. All of the securities in the
offering are to be sold by Gamida Cell.
Gamida Cell intends to use the net proceeds from this offering,
together with its existing cash and cash equivalents and trading
financial assets: to fund (i) commercialization activities to
support the launch of Omisirge®; (ii) the continued clinical
development of GDA-201; and (iii) general corporate purposes,
including general and administrative expenses and working
capital.
Piper Sandler & Co. is acting as sole book-running manager
for this offering.
A registration statement on Form S-3 (File No. 333-259472)
relating to the ordinary shares has been filed with the Securities
and Exchange Commission and declared effective on April 1, 2022.
This offering will be made only by means of a prospectus
supplement. Copies of the preliminary prospectus supplement and the
accompanying prospectus related to this offering may be obtained,
when available, from: Piper Sandler & Co., 800 Nicollet Mall,
J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus
Department, by telephone at (800) 747-3924 or by email at
prospectus@psc.com. Investors may also obtain these documents at no
cost by visiting the SEC’s website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Gamida Cell
Gamida Cell is a cell therapy pioneer working to turn cells into
powerful therapeutics. The company’s research and development
efforts have produced potentially curative cell therapy candidates
for patients with blood cancers. The company applies a proprietary
expansion platform leveraging the properties of nicotinamide to
cell sources including umbilical cord blood-derived cells and NK
cells to create allogeneic cell therapy candidates with the
potential to redefine standards of care. These include Omisirge, an
advanced cell therapy candidate for allogeneic hematopoietic stem
cell transplant that has the potential to expand access and improve
outcomes for patients with blood cancers, and GDA-201, an intrinsic
NK cell therapy candidate being investigated for the treatment of
hematological malignancies.
Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to whether Gamida Cell will consummate
the offering of securities described herein, and the timing, size
and use of proceeds of such offering, and its expectations with
respect to granting the underwriters a 30-day option to purchase
additional ordinary shares. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions,
including those that are described in the Risk Factors sections of
the preliminary prospectus supplement for such offering to be filed
with the SEC, and the documents incorporated by reference therein,
including without limitation the Company’s Annual Report on Form
10-K filed with the SEC on March 31, 2023, the accompanying
prospectus and other filings that Gamida Cell makes with the SEC
from time to time (which are available at http://www.sec.gov), any
of which could cause the events and circumstances discussed in such
forward-looking statements to not occur on the terms described or
at all. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date hereof. Gamida Cell undertakes no obligation to update any
such forward-looking statements after the date hereof, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230418006253/en/
Investor and Media Contact: Mike Kuczkowski Orangefiery
media@orangefiery.com 1-917-865-3213
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Aug 2023 to Aug 2024